Bluejay Diagnostics Completes 1-for-4 Reverse Stock Split

An announcement from Bluejay Diagnostics ( (BJDX) ) is now available.

On June 18, 2025, stockholders of Bluejay Diagnostics approved an amendment to the company’s charter to permit a reverse stock split at ratios between 1-for-2 and 1-for-20, and on January 27, 2026 the board selected a 1-for-4 ratio, filing a certificate of amendment in Delaware to implement the move. The 1-for-4 reverse stock split took effect at 12:01 a.m. Eastern Time on January 29, 2026, after which Bluejay’s common stock began trading on Nasdaq on a post-split basis under the unchanged ticker “BJDX” but with a new CUSIP, consolidating every four outstanding shares into one and cutting the share count from about 2,834,133 to roughly 708,533, with prefunded warrant shares and all equity awards and warrants adjusted proportionately. The reverse split, which leaves par value and voting rights intact and treats all stockholders uniformly, is operationally significant because it sharply reduces the number of shares outstanding while preserving ownership percentages, and it streamlines the capital structure for investors and warrant holders, who will see automatic adjustments in book-entry and street-name accounts and receive cash in lieu of fractional shares.

The most recent analyst rating on (BJDX) stock is a Hold with a $0.87 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Spark’s Take on BJDX Stock

According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.

The score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, and sustained negative free cash flow) despite low debt. Technicals add only modest support with a short-term bounce but a longer-term downtrend. Corporate events are positive for operational progress, but long regulatory/financing timelines and a negative P/E keep overall risk elevated.

To see Spark’s full report on BJDX stock, click here.

More about Bluejay Diagnostics

Bluejay Diagnostics, Inc., based in Acton, Massachusetts, is a medical diagnostics company developing the Symphony System, a cost-effective, rapid, near-patient testing platform aimed at sepsis triage and monitoring disease progression in critical care settings. Its first product candidate is an IL-6 test for sepsis designed to deliver results in about 20 minutes, though the Symphony System has not yet received U.S. Food and Drug Administration clearance and cannot currently be marketed as a diagnostic product in the United States.

Average Trading Volume: 45,302

Technical Sentiment Signal: Sell

Current Market Cap: $5.89M

For detailed information about BJDX stock, go to TipRanks’ Stock Analysis page.